Compare Stocks: CALT, INDV, OGN, and RGC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
INDV Indivior	$36.01 +1.6%	$36.35	$22.95 ▼ $42.81	$4.25B	0.87	2.16 million shs	317,232 shs
OGN Organon & Co.	$13.82 +0.5%	$13.70	$5.69 ▼ $13.81	$3.63B	1.55	5.23 million shs	1.37 million shs
RGC Regencell Bioscience	$7.52 -1.4%	$5.95	$4.51 ▼ $69.00	$3.72B	1.18	282,499 shs	64,553 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
INDV Indivior	-1.88%	+0.20%	+3.29%	-12.47%	+47.28%
OGN Organon & Co.	+0.01%	+0.37%	+0.08%	+1.93%	+34.40%
RGC Regencell Bioscience	+7.31%	+20.54%	+11.88%	+29.76%	-60.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
INDV Indivior	$36.01 +1.6%	$36.35	$22.95 ▼ $42.81	$4.25B	0.87	2.16 million shs	317,232 shs
OGN Organon & Co.	$13.82 +0.5%	$13.70	$5.69 ▼ $13.81	$3.63B	1.55	5.23 million shs	1.37 million shs
RGC Regencell Bioscience	$7.52 -1.4%	$5.95	$4.51 ▼ $69.00	$3.72B	1.18	282,499 shs	64,553 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
INDV Indivior	-1.88%	+0.20%	+3.29%	-12.47%	+47.28%
OGN Organon & Co.	+0.01%	+0.37%	+0.08%	+1.93%	+34.40%
RGC Regencell Bioscience	+7.31%	+20.54%	+11.88%	+29.76%	-60.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
INDV Indivior	3.00	Buy	$45.17	25.43% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.48% Downside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CALT, INDV, OGN, and RGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	INDV Indivior	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/24/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/21/2026	RGC Regencell Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/4/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/7/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/5/2026	INDV Indivior	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$46.00 ➝ $43.00
8/4/2026	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$53.00
8/3/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/24/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
7/13/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
INDV Indivior	$1.24B	3.43	$2.71 per share	13.28	($0.78) per share	-46.17
OGN Organon & Co.	$6.22B	0.58	$5.80 per share	2.38	$2.89 per share	4.78
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
INDV Indivior	$210M	$2.79	12.91	9.40	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.94	4.02	1.28	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CALT, INDV, OGN, and RGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	INDV Indivior	$1.06	N/A	N/A	N/A	$329.35 million	N/A
10/7/2026	Q4 2026	RGC Regencell Bioscience	N/A	-$0.0060	N/A	-$0.0060	N/A	N/A
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
RGC Regencell Bioscience	$0.88	11.70%	N/A	N/A	N/A

Latest CALT, INDV, OGN, and RGC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/16/2026	INDV Indivior	special	$8.13		10/30/2026	10/30/2026	11/6/2026
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
INDV Indivior	N/A	0.84	0.66
OGN Organon & Co.	8.43	1.95	1.44
RGC Regencell Bioscience	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
INDV Indivior	60.33%
OGN Organon & Co.	77.43%
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
INDV Indivior	0.74%
OGN Organon & Co.	1.62%
RGC Regencell Bioscience	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
INDV Indivior	838	118.03 million	117.16 million	Not Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
RGC Regencell Bioscience	10	494.49 million	484.60 million	N/A

CALT, INDV, OGN, and RGC Headlines

Recent News About These Companies

Is Regencell Bioscience Holdings (RGC) Fully Priced After Its Annual Loss Deepened?

October 8 at 7:00 PM | finance.yahoo.com

Regencell Bioscience (NASDAQ:RGC) Stock Jumps 0.3% - Time to Buy?

October 1, 2026 | americanbankingnews.com

Regencell Bioscience: I Got It Wrong (Rating Downgrade)

September 23, 2026 | seekingalpha.com

RGC Resources: More Likely To Appeal More To Income-Focused Investors

August 18, 2026 | seekingalpha.com

Regencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-K

July 3, 2026 | theglobeandmail.com

Regencell Bioscience surges on apparent short squeeze

July 1, 2026 | msn.com

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...

June 30, 2026 | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

June 23, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 23, 2026 | prnewswire.com

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 23, 2026 | businesswire.com

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

June 23, 2026 | globenewswire.com

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

June 23, 2026 | prnewswire.com

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

June 23, 2026 | tmcnet.com

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 23, 2026 | prnewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | tmcnet.com

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

June 22, 2026 | globenewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | businesswire.com

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 22, 2026 | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 22, 2026 | globenewswire.com

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...

June 21, 2026 | gazettextra.comG

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, INDV, OGN, and RGC Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 10/8/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Indivior NASDAQ:INDV

$36.08 +0.63 (+1.76%)

As of 01:30 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organon & Co. NYSE:OGN

$13.82 +0.08 (+0.55%)

As of 01:29 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Regencell Bioscience NASDAQ:RGC

$7.52 -0.11 (-1.44%)

As of 01:26 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALT, INDV, OGN, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALT, INDV, OGN, and RGC Earnings

Compare Dividends

Latest CALT, INDV, OGN, and RGC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALT, INDV, OGN, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, INDV, OGN, and RGC Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALT, INDV, OGN, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALT, INDV, OGN, and RGC Earnings

Compare Dividends

Latest CALT, INDV, OGN, and RGC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALT, INDV, OGN, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, INDV, OGN, and RGC Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools